Extreme Investor Network

Trial shows Gilead’s Lenacapavir reduces HIV infections by 96%

September 14, 2024

Gilead Lenacapavir cut HIV infections by 96% in trial

Introducing the Future of HIV Prevention: Gilead’s Lenacapavir Exciting news in the world of healthcare as Gilead announces groundbreaking results from a second large study on their innovative HIV prevention injectable drug, lenacapavir. According to … Read more

Successful Phase 3 Trial of Gilead’s PrEP Lenacapavir

June 20, 2024

Gilead PrEP lenacapavir succeeds in Phase 3 trial

Introducing Groundbreaking HIV Prevention Technology: Gilead’s Lenacapavir Shot Gilead recently made a groundbreaking announcement that has the potential to revolutionize HIV prevention. Their experimental twice-yearly medicine, lenacapavir, was shown to be 100% effective in preventing … Read more